Abstract
Aberrant proliferation of vascular smooth muscle cells [VSMCs] is implicated in the pathogenesis of vascular pathologies such as atherosclerosis and restenosis. Accumulating evidences have revealed that microRNAs are involved in cell proliferation in various pathological conditions. In the present study, we showed that miR-136 was up regulated in human coronary atherosclerotic plaques when compared with normal coronary artery tissues. Moreover, miR-136 levels were up regulated in proliferative vascular smooth muscle cells induced by platelet-derived growth factor [PDGF] or serum. In cultured VSMCs, over expression of miR-136 stimulated cell proliferation. PPP2R2A was proved to be the direct target gene of miR-136 and knockdown of PPP2R2A had a proliferative effect on VSMCs. miR-136-induced PPP2R2A down-regulation was accompanied by increased expression of ERK1/2 phosphorylation. Inhibition of ERK1/2 abolished the effect of miR-136 and knockdown of PPP2R2A on VSMCs proliferation. In summary, aberrant miR-136 up regulation in atherosclerosis contributes to abnormal VSMC proliferation through suppressing the ERK1/2 pathway by targeting PPP2R2A. Our study also suggested that specific modulation of miR-136 in human VSMCs may provide a potential approach for the treatment of atherosclerosis.
Keywords: Atherosclerosis, microRNA, miR-136, proliferation, vascular smooth muscle cells.
Current Vascular Pharmacology
Title:MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Volume: 13 Issue: 3
Author(s): Chun-feng Zhang, Kai Kang, Xin-miao Li and Bao-dong Xie
Affiliation:
Keywords: Atherosclerosis, microRNA, miR-136, proliferation, vascular smooth muscle cells.
Abstract: Aberrant proliferation of vascular smooth muscle cells [VSMCs] is implicated in the pathogenesis of vascular pathologies such as atherosclerosis and restenosis. Accumulating evidences have revealed that microRNAs are involved in cell proliferation in various pathological conditions. In the present study, we showed that miR-136 was up regulated in human coronary atherosclerotic plaques when compared with normal coronary artery tissues. Moreover, miR-136 levels were up regulated in proliferative vascular smooth muscle cells induced by platelet-derived growth factor [PDGF] or serum. In cultured VSMCs, over expression of miR-136 stimulated cell proliferation. PPP2R2A was proved to be the direct target gene of miR-136 and knockdown of PPP2R2A had a proliferative effect on VSMCs. miR-136-induced PPP2R2A down-regulation was accompanied by increased expression of ERK1/2 phosphorylation. Inhibition of ERK1/2 abolished the effect of miR-136 and knockdown of PPP2R2A on VSMCs proliferation. In summary, aberrant miR-136 up regulation in atherosclerosis contributes to abnormal VSMC proliferation through suppressing the ERK1/2 pathway by targeting PPP2R2A. Our study also suggested that specific modulation of miR-136 in human VSMCs may provide a potential approach for the treatment of atherosclerosis.
Export Options
About this article
Cite this article as:
Zhang Chun-feng, Kang Kai, Li Xin-miao and Xie Bao-dong, MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/1570161112666141118094612
DOI https://dx.doi.org/10.2174/1570161112666141118094612 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Recurrent Scalp Lesions from Glioblastoma: Case Report and Literature Review
Current Cancer Therapy Reviews Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology A Transporter Gene (Sodium Iodide Symporter) for Dual Purposes in Gene Therapy: Imaging and Therapy
Current Gene Therapy Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Tumor-related Molecular Regulatory Mechanisms of Long Non-coding RNA RMST: Recent Evidence
Mini-Reviews in Medicinal Chemistry Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Subject Index To Volume 7
Current Drug Targets A New Approach for Skin-Derived Precursors to Ameliorate Skin Photodamage Through Activation of Nrf2 Signaling Pathway
Current Signal Transduction Therapy The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Tumour Gene Therapy Monitoring Using Magnetic Resonance Imaging and Spectroscopy
Current Gene Therapy DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Use of Carbohydrate-Conjugated Nanoparticles for an Integrated Approach to Functional Imaging of Glycans and Understanding of their Molecular Mechanisms
Current Pharmaceutical Biotechnology Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry